antimitotic drug
Recently Published Documents


TOTAL DOCUMENTS

55
(FIVE YEARS 6)

H-INDEX

20
(FIVE YEARS 2)

Nanomaterials ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 3257
Author(s):  
Lorena Simón-Gracia ◽  
Kristina Kiisholts ◽  
Vilma Petrikaitė ◽  
Allan Tobi ◽  
Merli Saare ◽  
...  

The current diagnostic and therapeutic strategies for endometriosis are limited. Although endometriosis is a benign condition, some of its traits, such as increased cell invasion, migration, tissue inflammation, and angiogenesis are similar to cancer. Here we explored the application of homing peptides for precision delivery of diagnostic and therapeutic compounds to endometriotic lesions. First, we audited a panel of peptide phages for the binding to the cultured immortalized endometriotic epithelial 12Z and eutopic stromal HESC cell lines. The bacteriophages displaying PL1 peptide that engages with angiogenic extracellular matrix overexpressed in solid tumors showed the strongest binding to both cell lines. The receptors of PL1 peptide, tenascin C domain C (TNC-C) and fibronectin Extra Domain-B (Fn-EDB), were expressed in both cells. Silver nanoparticles functionalized with synthetic PL1 peptide showed specific internalization in 12Z and HESC cells. Treatment with PL1-nanoparticles loaded with the potent antimitotic drug monomethyl auristatin E decreased the viability of endometriotic cells in 2D and 3D cultures. Finally, PL1-nanoparticless bound to the cryosections of clinical peritoneal endometriotic lesions in the areas positive for TNC-C and Fn-EDB immunoreactivities and not to sections of normal endometrium. Our findings suggest potential applications for PL1-guided nanoparticles in precision diagnosis and therapy of endometriosis.


Molecules ◽  
2020 ◽  
Vol 25 (15) ◽  
pp. 3502
Author(s):  
Laura Del Coco ◽  
Maria Majellaro ◽  
Angelina Boccarelli ◽  
Saverio Cellamare ◽  
Cosimo Damiano Altomare ◽  
...  

A 1H-NMR-based metabolomic study was performed on MCF-7 cell lines treated with a novel nicotinamide derivative (DT-8) in comparison with two drugs characterized by a well-established mechanism of action, namely the DNA-metalating drug cisplatin (cis-diamminedichloridoplatinum(II), CDDP) and the antimitotic drug vinblastine (vinblastine, VIN). The effects of the three compounds, each one at the concentration corresponding to the IC50 value, were investigated, with respect to the controls (K), by the 1H-NMR of cells lysates and multivariate analysis (MVA) of the spectroscopic data. Relevant differences were found in the metabolic profiles of the different treatments with respect to the controls. A large overlap of the metabolic profiles in DT-8 vs. K and VIN vs. K suggests a similar biological response and mechanism of action, significantly diverse with respect to CDDP. On the other hand, DT8 seems to act by disorganizing the mitotic spindle and ultimately blocking the cell division, through a mechanism implying methionine depletion and/or S-adenosylmethionine (SAM) limitation.


2020 ◽  
Vol 27 (8) ◽  
pp. 2297-2312 ◽  
Author(s):  
Manuel D. Haschka ◽  
Gerlinde Karbon ◽  
Claudia Soratroi ◽  
Katelyn L. O’Neill ◽  
Xu Luo ◽  
...  

2019 ◽  
Author(s):  
Patrick J Burke ◽  
Joseph Z Hamilton ◽  
Thomas A Pires ◽  
Kim K Emmerton ◽  
Peter D Senter ◽  
...  

2018 ◽  
Vol 24 (6) ◽  
pp. 664-667
Author(s):  
Evangelos Drosos ◽  
Dimitrios Giakoumettis ◽  
Marios S. Themistocleous

Background: Colchicine is an ancient drug. Many uses have been reported in medical books and reports through the centuries. Currently the understanding of its mechanism of action has opened new horizons to its use. Objective: This article aims to discuss the use of colchicine in various neurosurgical conditions. Methods: A pubmed database and clinical trials search was performed, using the key words “colchicine”, “Neurosurgery”, “low back pain”, “stroke” and glioma”. Results: Various reports were found contemplating the use of colchicine in chronic low-back pain. The effect of the drug on neutrophil chemotaxis and its role as an anti-inflammatory agent has been the main argument upon which such use of colchicine has been structured. These characteristics have been the key to initiate colchicine as a preventive agent in vascular conditions. Furthermore, as colchicine is an antimitotic drug, it is currently being studied as a potential anti-glioma agent. However, the narrow therapeutic index of the drug is a discouraging factor in clinical application of colchicine in these entities. Therefore, colchicine derivatives that can exert the same effectiveness in lower doses are being studied, forming a new direction in colchicine use. Conclusion: Colchicine is a drug that over the years has shown promising results in certain neurosurgical entities. Its derivatives or potential colchicine-like agents might have a more significant place in neurosurgical practice.


2016 ◽  
Vol 513 (1-2) ◽  
pp. 464-472 ◽  
Author(s):  
Shahrouz Taranejoo ◽  
Mohsen Janmaleki ◽  
Mohammad Pachenari ◽  
Seyed Morteza Seyedpour ◽  
Ramya Chandrasekaran ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document